Boehringer's departing finance head had 'divergent views' on strategy

18 December 2017
boehringer-ingelheim-big

In a candid admission, privately-owned German pharma major Boehringer Ingelheim has said that conflicting views over strategy are behind the departure of one of its most senior executives.

Simone Menne, the member of the board of managing directors responsible for the finance corporate board division, is to leave the company at the end of the year.

Ms Menne is a former chief financial officer at Lufthansa, Germany’s largest airline, and only joined Boehringer in September 2016.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical